| scholarly article | Q13442814 |
| P50 | author | Barbara Ensoli | Q21255143 |
| Marjorie Robert-Guroff | Q30651738 | ||
| P2093 | author name string | Peng Xiao | |
| Aurelio Cafaro | |||
| Thorsten Demberg | |||
| David Venzon | |||
| Kay Larsen | |||
| L Ebonita Summers | |||
| LaRene Kuller | |||
| Ruth H Florese | |||
| P2860 | cites work | Tat protein induces self-perpetuating permissivity for productive HIV-1 infection | Q24683211 |
| Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF-kappa B binding and protein kinase C activity in primary human astrocytes | Q24683736 | ||
| Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial | Q28305565 | ||
| Cellular uptake of the tat protein from human immunodeficiency virus | Q29620627 | ||
| Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants | Q30976921 | ||
| Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein | Q31135334 | ||
| Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression | Q45844475 | ||
| Failure of ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort | Q45883512 | ||
| Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. | Q45987356 | ||
| Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV. | Q46588920 | ||
| Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate | Q46775963 | ||
| Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients | Q47216468 | ||
| An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. | Q52840793 | ||
| A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. | Q52841139 | ||
| The therapeutic phase I trial of the recombinant native HIV-1 Tat protein | Q57665211 | ||
| Candidate HIV-1 Tat vaccine development: from basic science to clinical trials | Q59647820 | ||
| The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS | Q61641064 | ||
| Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag | Q61641083 | ||
| Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses | Q64377680 | ||
| Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251 | Q64378954 | ||
| Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies | Q67674705 | ||
| IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages | Q67999489 | ||
| HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression | Q71396764 | ||
| Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine | Q77296129 | ||
| Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS | Q78678676 | ||
| Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains | Q33785321 | ||
| Nef from pathogenic simian immunodeficiency virus is a negative factor for vaccinia virus | Q33840818 | ||
| Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells | Q33844334 | ||
| Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies | Q33911986 | ||
| The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals | Q34104267 | ||
| The trans-activator gene of HTLV-III is essential for virus replication | Q34161962 | ||
| HIV-1 Tat vaccines | Q34556390 | ||
| HIV-1 Tat-based vaccines: from basic science to clinical trials | Q34978901 | ||
| Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV. | Q35023530 | ||
| Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys | Q35123128 | ||
| Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. | Q35182076 | ||
| A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe | Q35785031 | ||
| A call for replicating vector prime-protein boost strategies in HIV vaccine design | Q35851801 | ||
| An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge | Q35898573 | ||
| Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. | Q36011366 | ||
| Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation | Q36639380 | ||
| Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting | Q36954239 | ||
| Passive immunization as tool to identify protective HIV-1 Env epitopes | Q37017827 | ||
| Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro | Q37387255 | ||
| Anti-HIV-1 ADCC. | Q38754869 | ||
| Tat-specific binding IgG and disease progression in HIV type 1-infected Ugandans | Q38876519 | ||
| Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. | Q39443021 | ||
| Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. | Q40291422 | ||
| Antibody-dependent cellular cytotoxicity via humoral immune epitope of Nef protein expressed on cell surface | Q40592103 | ||
| Why do we not have an HIV vaccine and how can we make one? . | Q40859536 | ||
| Antibody-dependent cellular cytotoxicity in HIV infections. | Q40993761 | ||
| HIV-1 Tat protein as a potential AIDS vaccine | Q41091310 | ||
| Human immunodeficiency virus type 1 Nef protein on the cell surface is cytocidal for human CD4+ T cells | Q41168546 | ||
| Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. | Q41267357 | ||
| Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein | Q41349382 | ||
| Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals | Q41471715 | ||
| Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1 | Q41471931 | ||
| Human immunodeficiency virus type 1 Tat protein protects lymphoid, epithelial, and neuronal cell lines from death by apoptosis. | Q41522490 | ||
| Expression of human immunodeficiency virus type 1 Nef antigen on the surface of acutely and persistently infected human T cells. | Q41530887 | ||
| Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients | Q41689302 | ||
| Clustered localization of oligomeric Nef protein of human immunodeficiency virus type 1 on the cell surface | Q42063537 | ||
| The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters | Q43671904 | ||
| Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. | Q43725371 | ||
| Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. | Q43984746 | ||
| Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection | Q44032654 | ||
| Development of a whole-virus multiplex flow cytometric assay for antibody screening of a specific pathogen-free primate colony | Q45423142 | ||
| In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity | Q45752500 | ||
| Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection | Q45756087 | ||
| Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. | Q45761033 | ||
| Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). | Q45838520 | ||
| Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection | Q45843965 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| immunization | Q1415366 | ||
| vaccine | Q134808 | ||
| P304 | page(s) | 3718-3727 | |
| P577 | publication date | 2009-03-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines | |
| P478 | volume | 182 |
| Q43743967 | A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities |
| Q37054470 | A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice |
| Q43973641 | A designed Tat immunogen generates enhanced anti-Tat C-terminal antibodies |
| Q57072187 | A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection |
| Q36023146 | A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques |
| Q36363866 | A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays |
| Q27318266 | AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity |
| Q34756684 | Activation of NK cells by ADCC responses during early HIV infection |
| Q37505357 | Activation of NK cells by HIV-specific ADCC antibodies: role for granulocytes in expressing HIV-1 peptide epitopes |
| Q35077677 | An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum |
| Q33627673 | Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies |
| Q42159772 | Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development |
| Q34982646 | Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses |
| Q36172128 | Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding |
| Q36363231 | Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family |
| Q33877513 | Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant |
| Q27320687 | Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells |
| Q54263363 | Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay. |
| Q34645502 | B cell responses to HIV-1 infection and vaccination: pathways to preventing infection |
| Q35156935 | Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection |
| Q46296261 | Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials |
| Q27333734 | Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines |
| Q92177871 | Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models |
| Q27022152 | Challenges in mucosal HIV vaccine development: lessons from non-human primate models |
| Q34592776 | Compromised NK cell-mediated antibody-dependent cellular cytotoxicity in chronic SIV/SHIV infection |
| Q33872445 | Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains |
| Q36674033 | Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus |
| Q36844746 | Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. |
| Q27675486 | Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding |
| Q35069126 | Early short-term antiretroviral therapy is associated with a reduced prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques |
| Q40529181 | Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b |
| Q40794254 | Exploring the benefits of antibody immune response in HIV-1 infection using a discrete model. |
| Q42257677 | Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention |
| Q34485178 | Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy |
| Q36252656 | HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans |
| Q35156674 | Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. |
| Q30404393 | Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review |
| Q30428189 | Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus. |
| Q34937296 | Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure |
| Q40071705 | Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models |
| Q37096865 | Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques |
| Q42284435 | Impaired natural killer cell-induced antibody-dependent cell-mediated cytotoxicity is associated with human immunodeficiency virus-1 disease progression |
| Q37592654 | Indian Long-term Non-Progressors Show Broad ADCC Responses with Preferential Recognition of V3 Region of Envelope and a Region from Tat Protein |
| Q33611645 | Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy |
| Q34540645 | Induction of immunity to human immunodeficiency virus type-1 by vaccination |
| Q34791232 | Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes |
| Q35167400 | Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies |
| Q36009232 | Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones |
| Q31138949 | Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques |
| Q27305234 | Live attenuated Rev-independent Nef¯SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaques |
| Q28728189 | Measurements of immune responses for establishing correlates of vaccine protection against HIV |
| Q64066666 | Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function |
| Q38719420 | Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner |
| Q36911772 | Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk |
| Q36957775 | Mucosal immunology of HIV infection |
| Q33966586 | Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques |
| Q37677278 | Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles |
| Q36797342 | Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity |
| Q37971867 | Neutralizing antibodies and control of HIV: moves and countermoves. |
| Q36011269 | New paradigms for HIV/AIDS vaccine development |
| Q33900595 | New paradigms for functional HIV-specific nonneutralizing antibodies |
| Q36223864 | New prospects for a preventive HIV-1 vaccine |
| Q35534563 | No acquisition: a new ambition for HIV vaccine development? |
| Q38652858 | Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo |
| Q34057711 | Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines |
| Q37113941 | Opportunities to exploit non-neutralizing HIV-specific antibody activity |
| Q35415717 | Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults |
| Q36736400 | Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens |
| Q90587538 | Primary Human Neutrophils Exhibit a Unique HIV-Directed Antibody-Dependent Phagocytosis Profile |
| Q35160124 | Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges |
| Q38645979 | Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys |
| Q40565908 | RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine. |
| Q34574409 | Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge |
| Q51743315 | Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated SHIV challenges. |
| Q35940685 | Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route |
| Q37547763 | Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques |
| Q38213061 | Role of Fc-mediated antibody function in protective immunity against HIV-1. |
| Q36708266 | Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine |
| Q27640572 | Structural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 Infection |
| Q30238730 | Survivors Remorse: antibody-mediated protection against HIV-1. |
| Q46632788 | Temporal variation in HIV-specific IgG subclass Abs during acute infection differentiates spontaneous controllers from chronic progressors. |
| Q64060305 | The Antibodiome-Mapping the Humoral Immune Response to HIV |
| Q27000889 | The Antibody Response against HIV-1 |
| Q37364423 | The effects of HIV Tat DNA on regulating the immune response of HIV DNA vaccine in mice |
| Q98177674 | Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women |
| Q55411165 | Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. |
| Q27332360 | Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection |
| Q35636394 | Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques |
| Q34810713 | Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia |
| Q93150656 | Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV |
Search more.